Frontier Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Frontier Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-59,511	Closed	-$6.66M	–	308
2019 Q1	$6.66M	Buy	+59,511	New	+$6.5M	0.05%	251
2015 Q4	–	Sell	-4,114	Closed	-$682K	–	370
2015 Q3	$682K	Sell	4,114 -39,879	-91%	-$8.77M	0.01%	316
2015 Q2	$10.6M	Buy	43,993 +18,265	+71%	+$4.86M	0.08%	260
2015 Q1	$7.26M	Sell	25,728 -4,925	-16%	-$1.07M	0.05%	282
2014 Q4	$4.78M	Buy	+30,653	New	+$5.66M	0.04%	297

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Frontier Capital Management's ICPT Position: Q2 2019 in Review

Frontier Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2019, closing a stake of 59,511 shares — an estimated $6.66M sold.

Frontier Capital Management first reported a position in ICPT in Q4 2014 and held it in 5 quarters. The position peaked at $10.6M in Q2 2015. 196 funds tracked by Wall St. Rank hold ICPT as of Q2 2019.

Frontier Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Frontier Capital Management sold 59,511 Intercept Pharmaceuticals, Inc. shares in Q2 2019, an estimated $6.66M.
Frontier Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and held it in 5 quarters.
Frontier Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $10.6M in Q2 2015.
196 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2019.

Based on Frontier Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.